Literature DB >> 2414122

Type III procollagen N-terminal peptides in experimental pulmonary fibrosis and human respiratory diseases.

Y Watanabe, K Yamaki, I Yamakawa, K Takagi, T Satake.   

Abstract

In order to detect the fibrotic response in lung-tissue, concentrations of type III procollagen N-terminal peptide (P-III-P) were examined in sera and bronchoalveolar lavage fluids from rabbits with bleomycin-induced pulmonary fibrosis, and in sera from patients with various respiratory diseases, using a radioimmunoassay method. In the bleomycin-induced pulmonary fibrosis, a significant (p less than or equal to 0.05) rise in P-III-P levels was observed in the lavage fluid at 7 days, and in the sera at 21 days after bleomycin treatment, with histological confirmation of pulmonary fibrosis. Many of the patients with pulmonary fibrotic changes had significantly elevated serum P-III-P level. In lung cancer patients, most of the post-radiation serum samples were found to have P-III-P levels greater than or equal to 18 ng/ml. These results suggest that the increase in P-III-P levels is the reflection of fibrotic changes in the lungs and that the clinical assessment of serum P-III-P level could be important in the early detection of pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2414122

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  3 in total

1.  Increased procollagen type III peptide in serum of rabbits exposed to diesel engine exhaust.

Authors:  T Suzuki; T Kanoh
Journal:  Bull Environ Contam Toxicol       Date:  1990-05       Impact factor: 2.151

2.  Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation.

Authors:  Jean-Marie Forel; Christophe Guervilly; Sami Hraiech; François Voillet; Guillemette Thomas; Claude Somma; Véronique Secq; Catherine Farnarier; Marie-Josée Payan; Stéphanie-Yannis Donati; Gilles Perrin; Delphine Trousse; Stéphanie Dizier; Laurent Chiche; Karine Baumstarck; Antoine Roch; Laurent Papazian
Journal:  Intensive Care Med       Date:  2014-10-30       Impact factor: 17.440

3.  Transpulmonary gradient of type III procollagen peptides: acute effects of cardio-pulmonary bypass.

Authors:  N K Harrison; G J Laurent; T W Evans
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.